Free Trial
OTCMKTS:PURE

PURE Bioscience 12/16/2024 Earnings Report

PURE Bioscience logo
$0.07 -0.01 (-11.11%)
As of 11:42 AM Eastern

PURE Bioscience EPS Results

Actual EPS
-$0.01
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

PURE Bioscience Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PURE Bioscience Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

PURE Bioscience Earnings Headlines

A new rule goes live in July — and the banks are quietly cashing in
A major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.
See More PURE Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PURE Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PURE Bioscience and other key companies, straight to your email.

About PURE Bioscience

PURE Bioscience (OTCMKTS:PURE), Inc., headquartered in San Diego, California, develops and commercializes antimicrobial solutions based on its proprietary stabilized chlorine dioxide technology. The company’s core offerings include hard surface disinfectants, produce wash systems and water treatment solutions designed to inactivate a broad spectrum of bacteria, viruses and fungi. PURE Bioscience serves a diverse customer base spanning food processors, hospitality operators, healthcare facilities and municipal water authorities worldwide.

Since its founding in 2001, PURE Bioscience has leveraged government-funded research and patented chemistry to build a scalable platform for next-generation biocide products. Early collaborations with the U.S. Department of Defense validated the technology’s potency and safety profile, paving the way for commercial launches such as PURE® Hard Surface, ORCA® low-dose produce wash and PUR+™ residential disinfectants. Over the years, the company has expanded its intellectual property portfolio to address emerging challenges in food safety, infection control and waterborne pathogen management.

Operating through direct sales, distributor networks and strategic partnerships, PURE Bioscience markets its products across North America, Europe and parts of Asia. The company tailors its offerings to meet regional regulatory standards and customer requirements, from small-scale restaurants to large agricultural operations. In addition to product sales, PURE Bioscience provides technical support and training services to optimize antimicrobial protocols in sectors where contamination control is critical.

The management team comprises industry professionals with backgrounds in chemical manufacturing, biotechnology and commercial operations, supported by a board of directors experienced in life sciences and industrial technology commercialization. Under this leadership, PURE Bioscience continues to pursue new market opportunities, enhance manufacturing capabilities and advance its mission of delivering safe, sustainable antimicrobial solutions to global customers.

View PURE Bioscience Profile

More Earnings Resources from MarketBeat